Hayden E. Klein

Research shows a sharp rise in bisphenol-attributable metabolic disease since 2000, with annual costs exceeding $250 billion in North America.

Semaglutide and tirzepatide led to the most weight loss across 22 trials, while liraglutide remains a cost-effective alternative as its patent expires.

Updated guidelines set lower systolic blood pressure goals, expanded risk-based treatment, and call for stronger implementation to close care gaps.

Researchers urged caution in interpreting DECAF Trial results that suggest daily coffee intake is linked to a lower risk of atrial fibrillation recurrence.

The trial did not meet its primary end point for reducing plaque progression.

Combining 3 standard therapies into a single pill improved outcomes for adults with heart failure with reduced ejection fraction.

New research suggests stress cardiac MRI could help diagnose angina and improve quality of life for patients whose arteries appear clear on angiography.

Only 4% of NIH prevention projects target health disparities, revealing a major gap between equity research and real-world implementation.

In a phase 3 trial, the investigational oral PCSK9 inhibitor enlicitide reduced LDL cholesterol by nearly 60% in adults with or at risk for ASCVD.

Experts at AHA 2025 outlined how digital tools, inclusive trials, and safer deprescribing can reshape cardiovascular care for aging adults.

Research shows how low-dose aspirin, lifestyle habits, and the Life’s Essential 8 checklist can affect cardiovascular risk in patients with type 2 diabetes.

Lisa Taylor-Swanson, PhD, explains how including Indigenous and Hispanic women in conversations around menopause care helps fine-tune interventions.

Despite social media frenzy, there is limited evidence around testosterone’s impact on muscle, mood, and other menopausal symptoms.

Oncology experts discuss the rapid advancements in cancer diagnostics and treatments, emphasizing the need for equitable access and infrastructure improvements.

Payers cited high upfront costs, long-term uncertainty, and narrow coverage criteria as factors continuing to limit access and reimbursement innovation.

Attorney General Ken Paxton claims the manufacturers marketed acetaminophen toward pregnant women despite the “known dangers” to unborn children.

New data reinforce elinzanetant’s safety, efficacy, and ability to improve sleep disturbances in menopausal women, independent of vasomotor symptom relief.

Early and lifelong trauma can intensify menopause symptoms and accelerate cardiovascular and brain aging, according to research.

Preclinical data suggest a possible synergistic interaction between estrogen and GLP-1 signaling, explains Regina Castaneda, MD.

US safety data show that elinzanetant caused few adverse events and no new liver-related concerns in women, James Simon, MD, explains.

Hormonal shifts drive fat redistribution, muscle loss, and bone decline—all risk factors for cardiovascular disease in women, says Brooke Aggarwal, EdD.

Treating vasomotor symptoms, sleep disturbance, and mood disorders can remove barriers to weight loss for women during menopause, experts say.

Which hormonal contraceptives are still safe, when should women stop using them, and what other benefits do they offer during the menopause transition?

Different cultural, linguistic, and systemic barriers could impact how Indigenous and Hispanic women access menopause care, said Lisa Taylor-Swanson, PhD.

Can women feel relief from tinnitus and burning mouth syndrome during perimenopause and menopause?

Experts also explained how hormone therapy can benefit women managing chronic conditions such as diabetes and hypertension on top of their menopause.

Researchers will present new findings on how menopause affects cardiovascular, brain, metabolic, and digestive health.

The 7-mg and 14-mg oral semaglutide tablets are now indicated to reduce the risk of major adverse cardiovascular events in adults with diabetes.

Remote monitoring and algorithm-based tools help pharmacists balance complex workloads in value-based care, says Lindsey Valenzuela, PharmD.

Adults with diabetes were 24% less likely to visit an emergency department in 2021 than in 2019.